430 related articles for article (PubMed ID: 22705914)
1. Generation of natural killer cells from hematopoietic stem cells in vitro for immunotherapy.
Luevano M; Madrigal A; Saudemont A
Cell Mol Immunol; 2012 Jul; 9(4):310-20. PubMed ID: 22705914
[TBL] [Abstract][Full Text] [Related]
2. Frozen cord blood hematopoietic stem cells differentiate into higher numbers of functional natural killer cells in vitro than mobilized hematopoietic stem cells or freshly isolated cord blood hematopoietic stem cells.
Luevano M; Domogala A; Blundell M; Jackson N; Pedroza-Pacheco I; Derniame S; Escobedo-Cousin M; Querol S; Thrasher A; Madrigal A; Saudemont A
PLoS One; 2014; 9(1):e87086. PubMed ID: 24489840
[TBL] [Abstract][Full Text] [Related]
3. Selection and expansion of natural killer cells for NK cell-based immunotherapy.
Becker PS; Suck G; Nowakowska P; Ullrich E; Seifried E; Bader P; Tonn T; Seidl C
Cancer Immunol Immunother; 2016 Apr; 65(4):477-84. PubMed ID: 26810567
[TBL] [Abstract][Full Text] [Related]
4. High log-scale expansion of functional human natural killer cells from umbilical cord blood CD34-positive cells for adoptive cancer immunotherapy.
Spanholtz J; Tordoir M; Eissens D; Preijers F; van der Meer A; Joosten I; Schaap N; de Witte TM; Dolstra H
PLoS One; 2010 Feb; 5(2):e9221. PubMed ID: 20169160
[TBL] [Abstract][Full Text] [Related]
5. An Improved Method to Produce Clinical-Scale Natural Killer Cells from Human Pluripotent Stem Cells.
Zhu H; Kaufman DS
Methods Mol Biol; 2019; 2048():107-119. PubMed ID: 31396935
[TBL] [Abstract][Full Text] [Related]
6. Modification of NK cell subset repartition and functions in granulocyte colony-stimulating factor-mobilized leukapheresis after expansion with IL-15.
Xiong Y; Mouginot M; Reppel L; Qian C; Stoltz JF; Bensoussan D; Decot V
Immunol Res; 2017 Dec; 65(6):1130-1138. PubMed ID: 29019081
[TBL] [Abstract][Full Text] [Related]
7. Potential therapeutic role of natural killer cells in cancer.
Woan K; Reddy V
Expert Opin Biol Ther; 2007 Jan; 7(1):17-29. PubMed ID: 17150016
[TBL] [Abstract][Full Text] [Related]
8. Targeting natural killer cells in cancer immunotherapy.
Guillerey C; Huntington ND; Smyth MJ
Nat Immunol; 2016 Aug; 17(9):1025-36. PubMed ID: 27540992
[TBL] [Abstract][Full Text] [Related]
9. NK cell-based cancer immunotherapy: from basic biology to clinical development.
Liu S; Galat V; Galat Y; Lee YKA; Wainwright D; Wu J
J Hematol Oncol; 2021 Jan; 14(1):7. PubMed ID: 33407739
[TBL] [Abstract][Full Text] [Related]
10. Harnessing NK Cell Memory for Cancer Immunotherapy.
Fehniger TA; Cooper MA
Trends Immunol; 2016 Dec; 37(12):877-888. PubMed ID: 27773685
[TBL] [Abstract][Full Text] [Related]
11. Natural killer cell-based adoptive immunotherapy eradicates and drives differentiation of chemoresistant bladder cancer stem-like cells.
Ferreira-Teixeira M; Paiva-Oliveira D; Parada B; Alves V; Sousa V; Chijioke O; Münz C; Reis F; Rodrigues-Santos P; Gomes C
BMC Med; 2016 Oct; 14(1):163. PubMed ID: 27769244
[TBL] [Abstract][Full Text] [Related]
12. Clinical-scale derivation of natural killer cells from human pluripotent stem cells for cancer therapy.
Knorr DA; Ni Z; Hermanson D; Hexum MK; Bendzick L; Cooper LJ; Lee DA; Kaufman DS
Stem Cells Transl Med; 2013 Apr; 2(4):274-83. PubMed ID: 23515118
[TBL] [Abstract][Full Text] [Related]
13. Natural killer-dendritic cell cross-talk in cancer immunotherapy.
Kalinski P; Mailliard RB; Giermasz A; Zeh HJ; Basse P; Bartlett DL; Kirkwood JM; Lotze MT; Herberman RB
Expert Opin Biol Ther; 2005 Oct; 5(10):1303-15. PubMed ID: 16197336
[TBL] [Abstract][Full Text] [Related]
14. Use of allogeneic NK cells for cancer immunotherapy.
Geller MA; Miller JS
Immunotherapy; 2011 Dec; 3(12):1445-59. PubMed ID: 22091681
[TBL] [Abstract][Full Text] [Related]
15. Emerging natural killer cell immunotherapies: large-scale ex vivo production of highly potent anticancer effectors.
Suck G; Koh MB
Hematol Oncol Stem Cell Ther; 2010; 3(3):135-42. PubMed ID: 20890071
[TBL] [Abstract][Full Text] [Related]
16. Ascorbic acid promotes proliferation of natural killer cell populations in culture systems applicable for natural killer cell therapy.
Huijskens MJ; Walczak M; Sarkar S; Atrafi F; Senden-Gijsbers BL; Tilanus MG; Bos GM; Wieten L; Germeraad WT
Cytotherapy; 2015 May; 17(5):613-20. PubMed ID: 25747742
[TBL] [Abstract][Full Text] [Related]
17. Toll-Like Receptors in Natural Killer Cells and Their Application for Immunotherapy.
Noh JY; Yoon SR; Kim TD; Choi I; Jung H
J Immunol Res; 2020; 2020():2045860. PubMed ID: 32377528
[TBL] [Abstract][Full Text] [Related]
18. Leveraging natural killer cells for cancer immunotherapy.
Grossenbacher SK; Aguilar EG; Murphy WJ
Immunotherapy; 2017 May; 9(6):487-497. PubMed ID: 28472904
[TBL] [Abstract][Full Text] [Related]
19. Human natural killer cells: news in the therapy of solid tumors and high-risk leukemias.
Pietra G; Vitale C; Pende D; Bertaina A; Moretta F; Falco M; Vacca P; Montaldo E; Cantoni C; Mingari MC; Moretta A; Locatelli F; Moretta L
Cancer Immunol Immunother; 2016 Apr; 65(4):465-76. PubMed ID: 26289090
[TBL] [Abstract][Full Text] [Related]
20. Cellular immunotherapy of malignancies using the clonal natural killer cell line NK-92.
Tonn T; Becker S; Esser R; Schwabe D; Seifried E
J Hematother Stem Cell Res; 2001 Aug; 10(4):535-44. PubMed ID: 11522236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
